BACKGROUND:Peripheral artery disease (PAD) is associated with high cardiovascular mortality and a poor quality of life. The AT1-receptor blocker telmisartan has been shown to have pleiotropic effects and it may also improve endothelial function. The aim of this study was to analyze the effects of telmisartan on absolute walking distance (WD) and endothelial function in patients with PAD. METHODS: In a single centre, single-blinded, prospective study, 36 patients with PAD at stage Fontaine II or higher and mild to moderate arterial hypertension were treated with telmisartan 40/80 mg once daily or placebo for 12 months. Primary endpoint was the improvement of the absolute treadmill WD. Flow-mediated vasodilation (FMD), carotid intima-media thickness (IMT), ankle-brachial index (ABI) and disease-related quality of life (DRQL) were examined as well. RESULTS: After 12 months, maximum WD increased by 26% in the telmisartan group (P < 0.001). However, in the placebo group it was comparable to baseline. FMD rose by 40% in the telmisartan group while it deteriorated in the placebo group (P < 0.001). IMT and ABI were comparable in both groups at baseline and did not change considerably after 12 months. In non-diabetic patients (72.2%), the ABI did not change in the placebo group, whereas it increased by 11% in the telmisartan group (P < 0.001). While the DRQL remained stable in the telmisartan group, placebo treatment was associated with a marked deterioration (P < 0.01). CONCLUSION:Telmisartan improves WD and endothelial function, the ABI in non-diabetic patients and it may prevent further loss of quality of life in patients with advanced PAD.
RCT Entities:
BACKGROUND:Peripheral artery disease (PAD) is associated with high cardiovascular mortality and a poor quality of life. The AT1-receptor blocker telmisartan has been shown to have pleiotropic effects and it may also improve endothelial function. The aim of this study was to analyze the effects of telmisartan on absolute walking distance (WD) and endothelial function in patients with PAD. METHODS: In a single centre, single-blinded, prospective study, 36 patients with PAD at stage Fontaine II or higher and mild to moderate arterial hypertension were treated with telmisartan 40/80 mg once daily or placebo for 12 months. Primary endpoint was the improvement of the absolute treadmill WD. Flow-mediated vasodilation (FMD), carotid intima-media thickness (IMT), ankle-brachial index (ABI) and disease-related quality of life (DRQL) were examined as well. RESULTS: After 12 months, maximum WD increased by 26% in the telmisartan group (P < 0.001). However, in the placebo group it was comparable to baseline. FMD rose by 40% in the telmisartan group while it deteriorated in the placebo group (P < 0.001). IMT and ABI were comparable in both groups at baseline and did not change considerably after 12 months. In non-diabeticpatients (72.2%), the ABI did not change in the placebo group, whereas it increased by 11% in the telmisartan group (P < 0.001). While the DRQL remained stable in the telmisartan group, placebo treatment was associated with a marked deterioration (P < 0.01). CONCLUSION:Telmisartan improves WD and endothelial function, the ABI in non-diabeticpatients and it may prevent further loss of quality of life in patients with advanced PAD.
Authors: John Deanfield; Ann Donald; Claudio Ferri; Cristina Giannattasio; Julian Halcox; Sean Halligan; Amir Lerman; Giuseppe Mancia; James J Oliver; Achille C Pessina; Damiano Rizzoni; Gian Paolo Rossi; Antonio Salvetti; Ernesto L Schiffrin; Stefano Taddei; David J Webb Journal: J Hypertens Date: 2005-01 Impact factor: 4.844
Authors: Christoph Schindler; Axel Mueller; Peter Bramlage; Wolfgang Boecking; Wilhelm Kirch; Johannes Schweizer Journal: Angiology Date: 2007-10-10 Impact factor: 3.619
Authors: Frank Beutner; Andrej Teren; Stephan Gielen; Gerhard Schuler; Kerstin Wirkner; Daniel Tiller; Markus Loeffler; Markus Scholz Journal: Clin Res Cardiol Date: 2012-05-15 Impact factor: 5.460
Authors: Monica Lisi; Matthias Oelze; Saverio Dragoni; Andrew Liuni; Sebastian Steven; Mary-Clare Luca; Dirk Stalleicken; Thomas Münzel; Franco Laghi-Pasini; Andreas Daiber; John D Parker; Tommaso Gori Journal: Clin Res Cardiol Date: 2012-06 Impact factor: 5.460
Authors: Jin Hee Jeong; Justin D Sprick; Dana DaCosta; Arshed A Quyyumi; Jeanie Park Journal: Kidney Blood Press Res Date: 2021-11-10 Impact factor: 2.687
Authors: Mary M McDermott; Lydia Bazzano; Charlotte A Peterson; Robert Sufit; Luigi Ferrucci; Kathryn Domanchuk; Lihui Zhao; Tamar S Polonsky; Dongxue Zhang; Donald Lloyd-Jones; Christiaan Leeuwenburgh; Jack M Guralnik; Melina R Kibbe; Kate Kosmac; Michael H Criqui; Lu Tian Journal: JAMA Date: 2022-10-04 Impact factor: 157.335